MSB 3.21% $1.13 mesoblast limited

Not sure if this was posted prior.From Feb 2021.Comparative...

  1. 100 Posts.
    lightbulb Created with Sketch. 65
    Not sure if this was posted prior.
    From Feb 2021.

    Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons

    https://hotcopper.com.au/data/attachments/3458/3458603-0b23b96a1a0b2107ef434826f06d7d5d.jpg
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.